I plan on adding some CPRX tomorrow. This IMO is a very cheap bio. Firdapse has very high chances of multiple use. They just had great data on LEMS and should get approval IMO. It just had very good stage 2 data with Firdapse for Spinal Muscular Atrophy as well. Also looking to start a stage 3 trial for MuSK antibody positive Myasthenic Gravis or MuSK MG. Also A phase III trial of Firdapse for the treatment of Congenital Myasthenic Syndromes (CMS), dubbed CMS-001, is underway, and top-line results from this trial are expected in the first half of 2018. SO this is another that is in phase 3 and expected data in mid 18. If Its approved for LEMS The approval should really start to generate cash flow. With the small OS, no debt, Nice insider ownership, and nice cash on hand this one looks very nice. Also the institutional ownership was up like 15% last Q. The baker brothers own 5 million shares and these guys have a pretty damn good track record in bio tech.
Per their last Q. They should be ready to go when they get that approval.
Their commercial plan has already been conducted with regard to pricing, market access, market research, our patient services program that we expect will be world class sales force sizing, gross to net calculation.
News 
Market Data 
Discover 
